Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial*

By Cantor† Louis B.   Safyan Eleonora   Liu Ching-Chi   Batoosingh Amy L.  

Current Medical Research and Opinion, Vol. 24, Iss. 7, 2008-07 ,pp. : 2035-2043

Informa Healthcare

Access to resources Recommend Favorite

Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with openangle glaucoma or ocular hypertension

By Franks Wendy    

Current Medical Research and Opinion, Vol. 22, Iss. 9, 2006-09 ,pp. : 1643-1649

Informa Healthcare

Access to resources Recommend Favorite

The intraocular pressure reducing effect of brinzolamide as adjunctive therapy to latanoprost

By Li Yim James F.T.   Montgomery Donald M.  

Current Medical Research and Opinion, Vol. 27, Iss. 8, 2011-08 ,pp. : 1499-1502

Informa Healthcare

Access to resources Recommend Favorite

Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database

By Lazaridou Marie-Noëlle   Montgomery Donald M. I.   Ho Whye Onn   Jaberoo David  

Current Medical Research and Opinion, Vol. 24, Iss. 10, 2008-10 ,pp. : 2725-2728

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and patient tolerability of preservative‐free latanoprost compared with preservative prostaglandin analogs in patients with ocular hypertension or glaucoma

By  

ACTA OPHTHALMOLOGICA, Vol. 94, Iss. S256, 2016-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite